SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-16-012814
Filing Date
2016-04-27
Accepted
2016-04-27 16:56:23
Documents
9
Period of Report
2015-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL AND TRANSITION REPORT OF FOREIGN PRIVATE ISSUERS f20f2015_biondvaxpharma.htm 20-F 2279154
2 CERTIFICATION f20f2015ex12i_biondvax.htm EX-12.1 16068
3 CERTIFICATION f20f2015ex12ii_biondvax.htm EX-12.2 11745
4 CERTIFICATION f20f2015ex13i_biondvax.htm EX-13.1 4413
5 CERTIFICATION f20f2015ex13ii_biondvax.htm EX-13.2 4340
6 GRAPHIC image_002.jpg GRAPHIC 76628
7 GRAPHIC image_003.jpg GRAPHIC 74987
8 GRAPHIC image_004.jpg GRAPHIC 53552
9 GRAPHIC fin_001.jpg GRAPHIC 7006
  Complete submission text file 0001213900-16-012814.txt   2609490
Mailing Address 14 EINSTEIN ST. NES-ZIONA L3 74036
Business Address 14 EINSTEIN ST. NES-ZIONA L3 74036 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1213
Type: 20-F | Act: 34 | File No.: 001-37353 | Film No.: 161596055
SIC: 2836 Biological Products, (No Diagnostic Substances)